Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key bre ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Tango Therapeutics (TNGX) stock plunged 28% Wednesday after the company announced updates on several drug candidates and released its Q3 earnings report. Read more here.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the ...

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...

On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be ...

INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. “Lilly had another strong growth quarter in Q3, with ...

During a clinical trial, researchers found that CDK4/CDK6 inhibitor Verzenio may have a huge impact on women battling early stage breast cancer by decreasing the likelihood of the cancer returning.

A council plans on battling “the plague” of shopping trolleys dumped in its rivers and streets by hitting supermarkets harder in the pocket. A wildlife reserve visitor centre has been damaged ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings. The American Society of Clinical Oncology ...